CARDIOPROGRESS
Foundation for the advancement of cardiology

Eating meat, including chicken, linked to heart disease risk in study Eating meat has been linked to heart disease in the latest study to suggest the food could pose some risk to our health.

Periodontitis increases the risk of suffering from future atherosclerotic cardiovascular disease It was already known, but so far there was no rigorous and exhaustive report that corroborated the link between periodontitis and the future risk of developing atherosclerotic cardiovascular disease. Now two of the international reference entities in the field of periodontal and cardiovascular health, the European Federation of Periodontics (VET) and the World Heart Federation (WHF), publish a consensus powerful that leaves no room for doubt.

PARTNER 2A Intermediate-Risk TAVR Five-Year Results Hit Print Late outcomes of transcatheter aortic valve replacement (TAVR) in the PARTNER 2A trial are now enshrined in the peer-reviewed literature.

New report reveals the role of physical activity in preventing and treating cardiovascular diseases The European Heart Network, in collaboration with the WHO European Office for the Prevention and Control of Noncommunicable Diseases, has published an important report on physical activity policies for cardiovascular health. Each year, cardiovascular diseases cause 3.9 million deaths in Europe and over 1.8 million deaths in the European Union. Physical inactivity increases the risk of cardiovascular diseases by more than 20%.

A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement Whether the direct factor Xa inhibitor rivaroxaban can prevent thromboembolic events after transcatheter aortic-valve replacement (TAVR) is unclear.

Ticagrelor Sans Aspirin Trial Answers Some Questions About DAPT Hi. My name is Robert Byrne. I'm an interventional cardiologist at the German Heart Center in Munich and am here at TCT 2019 in San Francisco, where we've seen some interesting results from the TWILIGHT study. I would like to discuss some of the implications of this study for clinical practice.

From Naysayer to Convert: Cardiologists Should Prescribe SGLT2 Inhibitors Сardiologists have largely resisted calls to get more involved in diabetes. The comments on the Medscape article "Cardiologists Must Get Up to Speed on Treating Diabetes" echoed the sentiments of many regarding sodium-glucose contransporter-2 (SGLT2) prescribing.

MITRA-FR at 2 Years: MitraClip Still No Better Than Med Therapy Patrice Wendling PARIS — An additional year of follow-up in the MITRA-FR trial confirm no added benefit of percutaneous repair of functional mitral regurgitation (MR) with the MitraClip (Abbott) compared with optimal medical therapy alone.

Daily Aspirin May Lower Risk for Fatty Liver Progression Taking daily aspirin may prevent progression of nonalcoholic fatty liver disease (NAFLD) to liver fibrosis and nonalcoholic steatopepatitis (NASH), according to a study published online May 8 in Clinical Gastroenterology and Hepatology.

Novel Carotid Filter Aims for Stroke Prevention in Afib Stroke prophylaxis with a novel permanent filter implanted in the carotid arteries is feasible for high risk atrial fibrillation (Afib) patients, a pilot trial showed.

CGM Use, GLP-1s, Drinking Water Key of 2025 ADA Standards The American Diabetes Association (ADA)’s Standards of Care — 2025 offer new guidance on broader use of continuous glucose monitoring (CGM), use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) beyond weight loss, management of metabolic dysfunction-associated liver disease (MAFLD), plus a strong endorsement for drinking water and much more.

ADA Advises Against Using Compounded GLP-1 RA Medications In a new statement, the American Diabetes Association (ADA) has advised against the use of compounded glucagon-like peptide 1 receptor agonist (GLP-1 RA) and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RA medication classes.

Personal income may increase risk of heart disease Income levels, if they are unstable, can easily turn into a stressor. However, the volatility of personal income could be having a more serious effect on people's heart health. It is often expected that a person's income will constantly rise until they reach retirement age.

Weight-Adjusted Aspirin Dosing: Evidence Builds in Primary Prevention Low-dose aspirin intended for primary prevention, typically 75 to 100 mg once daily, doesn"t protect against cardiovascular events in persons who weigh at least 70 kg (about 154 pounds), suggests a patient-level analysis of randomized trials that included more than 100,000 patients. But daily aspirin at higher dosages, usually at least 300 mg, was cardioprotective in that group, as was low-dose aspirin in people who weighed less than 70 kg.

New ADA/EASD Guidance on Diabetes: Assess CV Status First The treatment approach to type 2 diabetes should begin with an assessment of cardiovascular disease (CVD) status, other comorbidities, and patient preferences, according to a draft of the upcoming 2018 joint consensus statement from the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD). The final version of the 2018 update to the current 2015 ADA/EASDManagement of Hyperglycemia in Type 2 Diabetes statement (Diabetes Care.2015;38:140-149) will be presented on October 5, 2018 at the EASD annual meeting in Berlin and will be published in Diabetes Care and Diabetologia.

The Asian and the Commonwealth of Independent States Congress of Cardiologists and Therapeutics

Expert opinion. Double antiplatelet therapy after ACS: "de-escalation" In medical practice, cases in which patients with acute coronary syndrome (ACS) and received a combination of acetylsalicylic acid (ASA) with prasugrel or ticagrelor are often used, a combination of ASA with clopidogrel is started. This transition from more active platelet-derived P2Y12 blockers to less active clopidogrel has been termed "de-escalation." The possibility of "de-escalation" is considered in documents prepared by various expert groups. Among them, an updated version of the recommendations of the European Society of Cardiology and the European Association of Cardio Thoracic Surgeons for double antiplatelet therapy for coronary heart disease, where a similar transition is proposed to be discussed with side effects or intolerance of prasugrel / ticagrelor. There is also an agreement of experts from Europe and the USA, in which practical approaches to the replacement of the P2Y12 blocker of the platelet receptor are analyzed in detail. However, it should be borne in mind that these proposals are basically based on common sense and representations of the pharmacological properties of various P2Y12 receptor blockers of the platelet, while the evidence base for "de-escalation" is small.

SUMMARY & CONCLUSIONS - 71ST WORLD HEALTH ASSEMBLY Global resolution on Rheumatic Fever and Rheumatic Heart Disease adopted at the WHA Following years of campaigning and advocacy from WHF, our members and the global RHD community, we are delighted to announce that on Friday 25 May, Member States of the World Health Organization unanimously adopted a Global Resolution on Rheumatic Fever and Rheumatic Heart Disease at the World Health Assembly in Geneva, Switzerland.

Bread Might Be The Saltiest Part Of Your Diet, According To A New Study When you think of salty foods, bread might not come to mind. But a new study shows that it may be a bigger contributor to sodium in your diet than you think. Even though it doesn"t taste that salty, bread might be delivering more sodium than you think — but it all depends on which kind you eat and how much, according to a new study. Researchers analyzed 2,000 different breads (including white, wholemeal, mixed grain, and flatbreads) sold in 32 countries around the world and found some shockingly high numbers and wide variation in the salt and sodium levels in breads. The study was conducted by the World Action on Salt & Health (WASH) at the Wolfson Institute of Preventive Medicine of Queen Mary University of London.

The Anti-statin Lobby Strikes Again: Time to Set the Record Straight The joint Franco-German non-commercial television network ARTE recently broadcast a television programme entitled "The Big Bluff" about the link between cholesterol, cardiovascular disease, and the use of statins. The programme propounded the theory that there is absolutely no relation between blood cholesterol levels and cardiovascular disease, and asserted that cholesterol has become the "ideal villain" in cardiovascular disease through a series of "scientific approximations". In addition, the programme encouraged physicians and patients to interrupt lipid-lowering treatments and statins, in particular, to avoid any blood lipid assessment and last but not least, suggested that the recommendations issued by professional societies such as the European Society of Cardiology (ESC) are inappropriate and influenced by conflicts of interest.